AZBT51105(Cancer Vaccine)

❖ Cancer vaccines : Using immunotherapy to recognize and eliminate cancer cells

Immune checkpoint inhibitor
* Prevent cancer cells from hiding by Inhibiting PD-1 checkpoint



Low response rate(20%~30%) adverse effects on immune system and tolerance

T cell immunotherapy(CAR-T)
* Reprogram a patient's own T cells with CAR



Low cure rate on solid cancer, side effects(CRS), expensive & complicated

Cancer vaccines
* Neoantigen helps T-Cell to recognize cancer cells better.



No Flagship : Clinical Trial Phase

Peptide vaccine, DNA vaccine, dendritic cell vaccine depends on type of peptide

❖ DDiSTA's technology



Tissue Prediction

Neoantigen and MHC Screening

Tumor Cell destruction by Activated T-cell

Point 1
Neoantigen Prediction

- Universal Antigen
- Tumor Associated Antigen
- Tumor Specific Antigen

Point 2
MHC Loading Prediction

- Antigen Presenting Cell
- MHC
- Peptide(Neoantigen)
- TCR
- T-cell

Point 3
Cell Penetrating ER Targeting



AZBT51105(Strength)

❖ Strength

- Unlike other cancer vaccines,
  1. It has a very simple structure, composed of CPP and Cargo.
  2. It delivers to the specific target, endoplasmic reticulum(ER).
  3. Its development cost is relative lower than other conventional drug discovery companies.
  4. Its manufacturing process and storing is relatively easy.

  In addition, it has less adverse effect because it uses human originated peptide sequence.

→ We would like to make cancer treatment become more simple, effective, accurate, safe, and most importantly affordable to worldwide cancer patients.

❖ Another strength of our pipeline is its expansional business innovation.

Growth Point 1
Optional Open Innovation



** NGS technology & Biomarker based (Precision Diagnosis) cancer vaccine platform*

Growth Point 2
Target-customized Cancer Vaccine

- Immune boost antigen
- Multi-antigen
- Common antigen

  for all cancers

→

- Personalized vaccine
- Specific cancer type
- Early stage cancer

  Metastatic cancer

  Recurrent cancer

Growth Point 3
Combination therapy

- Combination therapy with other drugs
- Peptide vaccine adjuvant